What is Regis Technologies?
Regis Technologies operates as a premier US-based Contract Development and Manufacturing Organization (CDMO) and a specialized manufacturer of chromatography products. The company provides a comprehensive suite of services, including cGMP manufacturing, analytical development, and custom API solutions for small molecule pharmaceutical development. By bridging the gap between discovery and commercial delivery, Regis Technologies serves as a vital partner for life sciences firms. Beyond its manufacturing prowess, the company maintains a robust portfolio of chromatography consumables, including HPLC and SFC columns, alongside specialty and imaging reagents, which are essential for high-fidelity analytical processes in modern laboratory environments.
How much funding has Regis Technologies raised?
Regis Technologies has raised a total of $3M across 2 funding rounds:
Debt
$1M
Debt
$2M
Debt (2020): $1M with participation from PPP
Debt (2021): $2M led by PPP
Key Investors in Regis Technologies
PPP
Public-Private Partnership
What's next for Regis Technologies?
With the recent capital deployment, Regis Technologies is well-positioned to accelerate its operational capacity and enhance its technical service offerings. The company is expected to focus on optimizing its cGMP manufacturing workflows and expanding its chromatography product line to meet the evolving demands of the global pharmaceutical sector. By leveraging this major strategic investment, Regis aims to deepen its integration into the drug development lifecycle, ensuring that its clients can navigate complex regulatory and technical hurdles with greater efficiency. Future growth will likely center on scaling analytical development capabilities and maintaining its reputation for precision in small molecule API production.
See full Regis Technologies company page
